Did revenue beats outshine wider losses, or did strong guidance save the day? A recent flurry of earnings reports reveals a complex landscape for investors, where some companies soared past revenue estimates, while others grappled with missed sales targets and deeper-than-expected losses, painting a varied picture of market performance.
Plug Power's Green Energy Surge
Hydrogen fuel cell company Plug Power (PLUG) sent a jolt through postmarket trading, seeing its stock pop after reporting strong fourth-quarter sales. The company posted revenues of [SOURCE:TipRanks] $225.22 million, comfortably outstripping the estimated $217.26 million.[/SOURCE] This revenue beat occurred despite a substantial $763 million in "various net charges" during the quarter, which weighed down other earnings metrics.However, the adjusted earnings per share (EPS – a company's profit divided by its outstanding shares) came in at -$0.06, better than the -$0.10 analysts had predicted. Management also reiterated its ambition to achieve positive EBITDAS (Earnings Before Interest, Taxes, Depreciation, Amortization, and Stock-based compensation) by 2026, stating the company is "positioned" to meet this goal.
Core Scientific's Bitcoin Blunder
In stark contrast, Core Scientific (CORZ), a bitcoin miner that has diversified into a data center company, plunged in postmarket trading. The culprit: significantly lower-than-expected sales for the final three months of 2025. Q4 revenues reached just $79.8 million, falling far short of the $115 million estimate.Adding to investor concerns, Core Scientific also revealed an accounting error, having overstated the value of its property, plant, and equipment in prior reports. While management assured that these restatements do not impact revenue, adjusted EBITDA, or net cash flows, the news sent shivers through the market. Notably, Core Scientific shareholders rejected a Q4 acquisition offer from CoreWeave, which aimed to create a more integrated "neocloud" provider.
Credo's Connectivity Conundrum
Credo Technology Group (CRDO), a provider of connectivity solutions, saw its shares decline by double digits postmarket. This downturn occurred despite solid third-quarter results, where revenues hit $407 million, slightly above the $406.4 million estimate, and adjusted EPS of $1.07 surpassed the $0.92 expectation.The primary concern was the company's Q4 guidance. Management projected sales to range between $425 million and $435 million, with the midpoint of $430 million landing just shy of Wall Street's $430.5 million call. Investors, who had previously boosted Credo's shares on preliminary Q3 figures and optimistic sales growth signals, reacted negatively to the "ho-hum" outlook.
Archer Aviation: Flying High on Defense Prospects
Air taxi manufacturer Archer Aviation reported a wider-than-expected fourth-quarter loss of $0.26 per share, compared to analyst estimates of $0.24 per share. The company's shares initially fell 2.4% after-hours. Looking ahead, Archer projected an adjusted EBITDA loss for Q1 between -$160 million and -$180 million, significantly deeper than Wall Street's expectation of -$104.7 million.Despite the losses, Archer ended 2025 with a robust $1.96 billion in cash and cash equivalents, up from $1.64 billion in Q3 and $834.5 million a year prior. The company also announced a partnership with SpaceX's Starlink for satellite internet in its Midnight aircraft and aims for its first passenger flights this year. CEO Adam Goldstein sees the defense business as the most promising near-term opportunity, focusing on autonomous, hybrid-electric VTOL (Vertical Take-Off and Landing) aircraft designed as a "loyal wingman" for armed reconnaissance helicopters. This strategic pivot may explain why Archer's shares closed up more than 5% on Monday, aligning with a broader rally in defense contractor stocks.
Hims & Hers: Peptide Potential Unlocked?
Hims & Hers, a telehealth platform, experienced a significant surge following remarks from Health and Human Services Secretary Robert F. Kennedy Jr. on the "Joe Rogan Experience" podcast. During the podcast, Kennedy expressed his desire to make approximately 14 peptides more accessible and allow for compounding, noting that the FDA is "looking at the science" behind these treatments.A more lenient regulatory stance on peptides – short chains of amino acids that regulate various bodily processes and are active ingredients in popular GLP-1 (Glucagon-like peptide-1 receptor agonists, a class of drugs used for diabetes and weight loss) medications – could unlock substantial new revenue opportunities for Hims & Hers. The market reaction suggests investors believe regulatory headwinds for the company might be shifting.
Broader Market Movements
Beyond individual corporate reports, the broader market experienced a volatile day, with stocks closing higher after whipsawing. Energy and defense stocks notably climbed following a series of U.S. attacks against Iran, while fuel-reliant travel assets saw declines. This geopolitical tension underscores how external events can swiftly reshape market sentiment across various sectors. For instance, (cnbc.com) energy transition and security remain core strategies for companies like Seatrium, as highlighted by its CEO.In other tech news, (cnbc.com) Nvidia's stock continued to perform well after beating its Q4 earnings expectations, a testament to the ongoing demand in the AI sector. Meanwhile, (cnbc.com) Salesforce shares slid following its quarterly results, even as CEO Marc Benioff pointed to "Agentic AI" as a future tailwind. These varied reactions reflect a market grappling with both company-specific fundamentals and broader macroeconomic and geopolitical forces.
